Relief Therapeutics Holding (XSWX:RLF) Selling, General, & Admin. Expense: CHF7.91 Mil (TTM As of Jun. 2025)


XSWX:RLF Relief Therapeutics Holding SA XSWX:RLF
20 GF Score
Price CHF3.00
GF Value CHF6.28
! 5 Warning Signs
View Full Analysis

What is Relief Therapeutics Holding Selling, General, & Admin. Expense?

Relief Therapeutics Holding XSWX:RLF +4.90% 20 Selling, General, & Admin. Expense is CHF7.91 Mil as of Jun. 2025. GuruFocus rates XSWX:RLF with a GF Score™ of 20/100 and a GF Value™ of CHF6.28. The stock has 5 warning signs investors should review.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Relief Therapeutics Holding's selling, general, & admin. expense for the six months ended in Jun. 2025 was CHF3.98 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Jun. 2025 was CHF7.91 Mil.


Relief Therapeutics Holding  (XSWX:RLF) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Relief Therapeutics Holding Selling, General, & Admin. Expense Related Terms


Relief Therapeutics Holding Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for Relief Therapeutics Holding's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Relief Therapeutics Holding Selling, General, & Admin. Expense Chart

Relief Therapeutics Holding Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.63 16.24 24.05 19.43 9.83

Relief Therapeutics Holding Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.16 8.27 5.90 3.93 3.98

XSWX:RLF vs KTTA, OSRH, LIMN: Selling, General, & Admin. Expense Comparison

For the Biotechnology subindustry, Relief Therapeutics Holding's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Relief Therapeutics Holding Selling, General, & Admin. Expense vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Relief Therapeutics Holding's Selling, General, & Admin. Expense falls into.


XSWX:RLF
20GF Score
Relief Therapeutics Holding SA XSWX:RLF
Selling, General, & Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Relief Therapeutics Holding Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF7.91 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of CHF7.91 Mil mean?
Relief Therapeutics Holding (XSWX:RLF) has a Selling, General, & Admin. Expense of CHF7.91 Mil as of Jun. 2025. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Relief Therapeutics Holding and its competitors.
Is Relief Therapeutics Holding's Selling, General, & Admin. Expense too high?
Relief Therapeutics Holding's current Selling, General, & Admin. Expense is CHF7.91 Mil. Overall, Relief Therapeutics Holding has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Relief Therapeutics Holding's Selling, General, & Admin. Expense compare to KTTA and OSRH?
Relief Therapeutics Holding's Selling, General, & Admin. Expense of CHF7.91 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Relief Therapeutics Holding and its competitors. Relief Therapeutics Holding's current Selling, General, & Admin. Expense is CHF7.91 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relief Therapeutics Holding stock overvalued right now?
Relief Therapeutics Holding (XSWX:RLF) has a current Selling, General, & Admin. Expense of CHF7.91 Mil. The stock's GF Value™ is CHF6.28, compared to a current price of CHF3.00 — trading 52.2% below its estimated fair value. The current Selling, General, & Admin. Expense is CHF7.91 Mil. Relief Therapeutics Holding's overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Relief Therapeutics Holding (XSWX:RLF), the current Selling, General, & Admin. Expense is CHF7.91 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Relief Therapeutics Holding (XSWX:RLF) Overvalued in 2026?

Based on GuruFocus' analysis, Relief Therapeutics Holding stock appears to be undervalued. The current stock price of CHF3.00 is trading 52.2% below its estimated GF Value™ of CHF6.28.

Key valuation signals for XSWX:RLF:

  • Selling, General, & Admin. Expense: CHF7.91 Mil
  • GF Value™: CHF6.28 vs. price of CHF3.00 (52.2% below fair value)
  • GF Score™: 20/100 with 5 warning signs

No single metric tells the full story. See the XSWX:RLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Relief Therapeutics Holding Business Description

Address Avenue de Secheron 15, Geneva, CHE, 1202
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.
20GF Score

Get the complete analysis for XSWX:RLF

Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF3.00
Price
CHF6.28
GF Value